⌕
NovoCure · NVCR · Nasdaq
Tenet 38 · Weak
Compare
$11.14−1.42%At closeTenet 38 · Weak
$11.14−0.16 (−1.42%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

NovoCure (NVCR) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is NVCR's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Business WireNov 13, 2026 · 11:30 ETEARNINGS EXPECTED BY FEB 10
JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fi…

NVCR −1.4% todayRead at source ↗
● The Motley FoolNov 10, 2026 · 13:50 ET
FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

Mya is an investigational product in the Optune line. These wearable devices generate electric fields that disrupt cell division, ideally preventing the spread of cancer.…

NVCR −1.4% todayRead at source ↗
● Business WireNov 9, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) applic…

NVCR −1.4% todayRead at source ↗
● Defense WorldNov 6, 2026 · 02:29 ETEARNINGS EXPECTED BY FEB 10
Head-To-Head Contrast: Flora Growth (NASDAQ:FLGC) & NovoCure (NASDAQ:NVCR)

NovoCure (NASDAQ: NVCR - Get Free Report) and Flora Growth (NASDAQ: FLGC - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the …

NVCR −1.4% todayRead at source ↗
● Zacks Investment ResearchNov 2, 2026 · 10:16 ET
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock

Explore how NovoCure's (NVCR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.…

NVCR −1.4% todayRead at source ↗
● The Motley FoolNov 1, 2026 · 21:23 ETEARNINGS EXPECTED BY FEB 10
NovoCure: 3 Key Takeaways for Long-Term Investors

NovoCure generated record third-quarter net revenue of $193 million. Active glioblastoma patients grew 11% year over year to 4,730.…

NVCR −1.4% todayRead at source ↗
● Seeking AlphaOct 29, 2026 · 19:58 ETEARNINGS EXPECTED BY FEB 10
NovoCure Limited (NVCR) Q3 2026 Earnings Call Transcript

NovoCure Limited ( NVCR ) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDT Company Participants Adam Daney - Head of Investor Relations William Doyle - Executive Chairman Frank Leonard - CEO & Director Christoph Brackm…

NVCR −1.4% todayRead at source ↗
● MarketBeatOct 29, 2026 · 16:15 ETEARNINGS EXPECTED BY FEB 10
NovoCure Q3 Earnings Call Highlights

NovoCure NASDAQ: NVCR reported third-quarter 2026 net revenue of $193 million, up 16% from a year earlier, as growth in its Optune Gio business and an expanding launch of Optune Lua in Japan helped lift active patient co…

NVCR −1.4% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 09:36 ETEARNINGS EXPECTED BY FEB 10
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates

NovoCure (NVCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.33 per share a year ago.…

NVCR −1.4% todayRead at source ↗
● Business WireOct 29, 2026 · 07:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 10
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) today reported financial results for the third quarter that ended September 30, 2026. Novocure is a global oncology company working to extend survival in some o…

NVCR −1.4% todayRead at source ↗
● Business WireOct 28, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure's Tumor Trea…

NVCR −1.4% todayRead at source ↗
● Defense WorldOct 19, 2026 · 06:14 ETEARNINGS EXPECTED BY FEB 10
NovoCure (NASDAQ:NVCR) and Ambu A/S (OTCMKTS:AMBBY) Head to Head Contrast

Ambu A/S (OTCMKTS:AMBBY - Get Free Report) and NovoCure (NASDAQ: NVCR - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of thei…

NVCR −1.4% todayRead at source ↗
● Seeking AlphaOct 13, 2026 · 11:30 ET
Novocure: A Mispriced Cash-Generating Biotech With Upside Potential

NovoCure is undervalued at a $1.66B market cap, with its pipeline and FDA-approved products not fully reflected in its price. NVCR's revenue grew 16% YoY to $183.58M, with international sales and patient adoption acceler…

NVCR −1.4% todayRead at source ↗
● Defense WorldOct 12, 2026 · 10:15 ETEARNINGS EXPECTED BY FEB 10
Reviewing NeurAxis (NASDAQ:NRXS) and NovoCure (NASDAQ:NVCR)

NeurAxis (NASDAQ: NRXS - Get Free Report) and NovoCure (NASDAQ: NVCR - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strengt…

NVCR −1.4% todayRead at source ↗
● Defense WorldOct 11, 2026 · 05:34 ETEARNINGS EXPECTED BY FEB 10
Critical Survey: Medline (NASDAQ:MDLN) & NovoCure (NASDAQ:NVCR)

NovoCure (NASDAQ: NVCR - Get Free Report) and Medline (NASDAQ: MDLN - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their pro…

NVCR −1.4% todayRead at source ↗
● Business WireOct 1, 2026 · 09:00 ET
Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable …

NVCR −1.4% todayRead at source ↗
● Defense WorldSep 28, 2026 · 03:24 ETEARNINGS EXPECTED BY FEB 10
NovoCure Limited $NVCR Stake Trimmed by Corient Private Wealth LP

Corient Private Wealth LP lessened its holdings in NovoCure Limited (NASDAQ: NVCR) by 71.5% in a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61,650 …

NVCR −1.4% todayRead at source ↗
● MarketBeatSep 18, 2026 · 10:02 ET
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even

NovoCure NASDAQ: NVCR outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Confe…

NVCR −1.4% todayRead at source ↗
● Seeking AlphaSep 14, 2026 · 18:51 ET
NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

NVCR −1.4% todayRead at source ↗
● Zacks Investment ResearchSep 7, 2026 · 12:15 ET
Novocure Reports Patient Data Exposure in Cybersecurity Incident

NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.…

NVCR −1.4% todayRead at source ↗
● Business WireSep 2, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Novocure Announces Upcoming Investor Events

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. Wells Fargo 21st Annual Healthcare Conference, September 9, 2026: Frank Leonar…

NVCR −1.4% todayRead at source ↗
● ReutersSep 1, 2026 · 07:54 ET
Oncology firm Novocure says cyberattack exposed US patient records

Oncology company Novocure said on Tuesday a cybersecurity incident involving unauthorized access ​to certain information systems in mid-August exposed ‌internal records of more than 1,400 U.S. patients.…

NVCR −1.4% todayRead at source ↗
● Zacks Investment ResearchAug 28, 2026 · 10:55 ETEARNINGS EXPECTED BY FEB 10
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earning…

NVCR −1.4% todayRead at source ↗
● Zacks Investment ResearchAug 20, 2026 · 13:01 ET
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice

Does NovoCure (NVCR) have what it takes to be a top stock pick for momentum investors? Let's find out.…

NVCR −1.4% todayRead at source ↗

Expected by Feb 10. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA26+3.4%
BAC3−1.3%
COST3−0.6%

Article counts from the last market-wide feed page, across every symbol we track and not just NVCR · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.